[Roxatidine acetate in therapy of reflux esophagitis].
A total of 3409 patients with gastro-oesophageal reflux disease were treated with roxatidine acetate. 60.7% of the patients received a daily dose of 2 x 75 mg roxatidine acetate, and the median duration of treatment was 5 weeks. Symptoms improved in about 90% of patients. For 1687 patients, endoscopic findings were available at the beginning and end of the treatment period. The overall endoscopic healing rate was 65.3%, and, depending on the initial finding (if), decreased from 92.9% (if: Savary-Miller stage I) to 67.5% (if: stage II), 40.7% (if: stage III), and to 22.5% (if: stage IV). Twenty-one patients experienced adverse events during the course of treatment, which, however, were either only minor or not related to the use of roxatidine acetate.
Friedrich
P
P
Städtisches Krankenhaus, Neustadt, Dresden.
Botzler
R
R
Mayershofer
R
R
Kriech
W
W
D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004945:Esophagoscopy; D005260:Female; D005764:Gastroesophageal Reflux / Q000145:classification / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*
D000897:Anti-Ulcer Agents; D010880:Piperidines; C053742:roxatidine acetate
Roxatidinazetat in der Therapie der Refluxösophagitis.